Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 145 Results

Title
Intervention Indication Therapeutic Area Year Actions
Tralokinumab for atopic dermatitis Tralokinumab (CAT-354; LP 0162) Atopic dermatitis Dermatology 2019 View  |  Download
Tofacitinib for polyarticular juvenile idiopathic arthritis Tofacitinib citrate (Xeljanz; CP-690550) Juvenile idiopathic arthritis Rheumatology 2019 View  |  Download
Tisotumab vedotin for recurrent or metastatic cervical cancer Tisotumab vedotin (HuMax-TF-ADC) Cervical cancer Female Reproductive Cancer 2019 View  |  Download
Ticagrelor in addition to acetylsalicylic acid for prevention of stroke in patients with acute ischaemic stroke or transient ischaemic attack Ticagrelor (Brilique; AZD6140) Stroke Cardiovascular System 2019 View  |  Download
Tezacaftor/ivacaftor (fixed-dose combination) for cystic fibrosis homozygous for F508del mutation in patients aged 6 to 11 years Ivacaftor (Kalydeco; VX-770) , Symkevi (fixed dose combination: Tezacaftor; Ivacaftor) Cystic fibrosis Genetic Disorders , Respiratory System 2019 View  |  Download
Tezacaftor/ivacaftor (fixed-dose combination) for cystic fibrosis heterozygous for F508del mutation and one residual mutation in patients aged 6 to 11 years Ivacaftor (Kalydeco; VX-770) , Symkevi (fixed dose combination: Tezacaftor; Ivacaftor) Cystic fibrosis Genetic Disorders , Respiratory System 2019 View  |  Download
Tezacaftor and ivacaftor for cystic fibrosis homozygous or heterozygous for F508del mutation in patients aged 12 years and older who discontinued treatment with Orkambi Ivacaftor (Kalydeco; VX-770) , Symkevi (fixed dose combination: Tezacaftor; Ivacaftor) Cystic fibrosis Genetic Disorders , Respiratory System 2019 View  |  Download
Tanezumab for moderate to severe chronic pain associated with osteoarthritis and chronic low back pain Tanezumab (PF-04383119; RN624) Back pain , Osteoarthritic pain Musculoskeletal System , Pain Relief , Rheumatology 2019 View  |  Download
Tabelecleucel for Epstein-Barr Virus-associated lymphoproliferative disease following solid organ transplant Tabelecleucel (Tab-cel; ATA129) Post-transplant lymphoproliferative disease (PTLD) Haematological Cancer and Lymphomas 2019 View  |  Download
Spartalizumab in addition to dabrafenib and trametinib for unresectable or metastatic BRAF V600 mutant melanoma – first‐line Dabrafenib (Tafinlar; GSK2118436; dabrafenib mesilate) , Spartalizumab (PDR001) , Trametinib (Mekinist; TMT212; GSK-1120212B; GSK1120212; JTP-74057; trametinib dimethyl sulfoxide) Melanoma Skin Cancer 2019 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications